Pheon Therapeutics

Pheon Therapeutics is a biotechnology company focused on developing next-generation Antibody-Drug Conjugates (ADCs) aimed at treating hard-to-treat solid tumors and liquid cancers.

Founded in 2015 and headquartered in Harpenden, Hertfordshire, the company leverages two decades of ADC experience to create a novel pipeline of advanced cancer treatments. The company’s lead program features a first-in-class ADC targeting a novel antigen expressed in various solid tumors. Pheon Therapeutics utilizes clinically validated monoclonal antibodies combined with proprietary drug payloads to enhance treatment efficacy. With approximately 25 employees, the company operates within the drug discovery, biotechnology, and oncology sectors, primarily serving the healthcare industry. Pheon Therapeutics is backed by significant venture capital, having raised around $188–$191 million to date, with plans to submit an Investigational New Drug application to the US FDA in the near future.